CA2088679A1 - Method for treating immune system dysfunctions - Google Patents
Method for treating immune system dysfunctionsInfo
- Publication number
- CA2088679A1 CA2088679A1 CA002088679A CA2088679A CA2088679A1 CA 2088679 A1 CA2088679 A1 CA 2088679A1 CA 002088679 A CA002088679 A CA 002088679A CA 2088679 A CA2088679 A CA 2088679A CA 2088679 A1 CA2088679 A1 CA 2088679A1
- Authority
- CA
- Canada
- Prior art keywords
- immune system
- lys
- dynorphin
- patient
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000987 immune system Anatomy 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000004064 dysfunction Effects 0.000 title description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims abstract description 66
- 108010065372 Dynorphins Proteins 0.000 claims abstract description 46
- 102100024622 Proenkephalin-B Human genes 0.000 claims abstract description 42
- 229960005181 morphine Drugs 0.000 claims abstract description 33
- 230000001771 impaired effect Effects 0.000 claims abstract description 11
- 230000001684 chronic effect Effects 0.000 claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 239000004084 narcotic analgesic agent Substances 0.000 claims abstract description 6
- 230000037396 body weight Effects 0.000 claims description 15
- 108010093625 Opioid Peptides Proteins 0.000 claims description 14
- 102000001490 Opioid Peptides Human genes 0.000 claims description 14
- 239000003399 opiate peptide Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 108010074881 dynorphin (1-13) Proteins 0.000 claims description 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 7
- AQZMRRKJJIQBDF-RAMXHLMLSA-N (2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomet Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(N)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 AQZMRRKJJIQBDF-RAMXHLMLSA-N 0.000 claims description 6
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 claims description 5
- 108010060886 dynorphin amide (1-10) Proteins 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 claims description 3
- RBEATVHTWHTHTJ-KKUMJFAQSA-N Lys-Leu-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O RBEATVHTWHTHTJ-KKUMJFAQSA-N 0.000 claims description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 2
- 229960002069 diamorphine Drugs 0.000 claims description 2
- -1 dynorphin (1-13) amide Chemical class 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 1
- 238000011127 radiochemotherapy Methods 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 239000008188 pellet Substances 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 13
- 210000001185 bone marrow Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000005757 colony formation Effects 0.000 description 7
- OVVIBUHLQIYUEU-IWIISZHXSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminometh Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 OVVIBUHLQIYUEU-IWIISZHXSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000002798 bone marrow cell Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 4
- 229960004127 naloxone Drugs 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000018526 Narcotic-Related disease Diseases 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- ILBHHEXPXBRSKB-FWEHEUNISA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ILBHHEXPXBRSKB-FWEHEUNISA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 210000003359 CD4-positive helper T lymphocyte Anatomy 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 101000642815 Homo sapiens Protein SSXT Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100108551 Mus musculus Akr1b7 gene Proteins 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 102000012543 Proenkephalin B Human genes 0.000 description 1
- 102100035586 Protein SSXT Human genes 0.000 description 1
- HIINQLBHPIQYHN-JTQLQIEISA-N Tyr-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 HIINQLBHPIQYHN-JTQLQIEISA-N 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000002791 cfu-m Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010074732 preproenkephalin Proteins 0.000 description 1
- 108010041071 proenkephalin Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010017156 tyrosyl-glycyl-glycyl-phenylalanyl-leucyl-arginine Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000004760 visceral afferent Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56239390A | 1990-08-03 | 1990-08-03 | |
| US562,393 | 1990-08-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2088679A1 true CA2088679A1 (en) | 1992-02-04 |
Family
ID=24246112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002088679A Abandoned CA2088679A1 (en) | 1990-08-03 | 1991-08-02 | Method for treating immune system dysfunctions |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0541694A1 (enExample) |
| JP (1) | JPH06501930A (enExample) |
| AU (1) | AU660420B2 (enExample) |
| CA (1) | CA2088679A1 (enExample) |
| WO (1) | WO1992002547A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817628A (en) * | 1992-12-02 | 1998-10-06 | The Rockefeller University | Dynorphin a suppression of natural killer cell activity |
| US20190241660A1 (en) * | 2017-12-05 | 2019-08-08 | Intendet Services, Llc | Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757049A (en) * | 1981-10-05 | 1988-07-12 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids |
| US4801614A (en) * | 1981-10-05 | 1989-01-31 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells |
| US4537878A (en) * | 1981-10-05 | 1985-08-27 | Tni Pharmaceuticals, Inc. | Process for using endogenous enkephalins and endorphins to stimulate the immune system |
-
1991
- 1991-08-02 EP EP91915040A patent/EP0541694A1/en not_active Withdrawn
- 1991-08-02 WO PCT/US1991/005518 patent/WO1992002547A1/en not_active Ceased
- 1991-08-02 AU AU84333/91A patent/AU660420B2/en not_active Ceased
- 1991-08-02 JP JP3514500A patent/JPH06501930A/ja active Pending
- 1991-08-02 CA CA002088679A patent/CA2088679A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU660420B2 (en) | 1995-06-29 |
| JPH06501930A (ja) | 1994-03-03 |
| AU8433391A (en) | 1992-03-02 |
| WO1992002547A1 (en) | 1992-02-20 |
| EP0541694A4 (enExample) | 1994-03-09 |
| EP0541694A1 (en) | 1993-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shavit et al. | Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity | |
| De Sarro et al. | Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone | |
| CA2225185A1 (en) | Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities | |
| CA2137916A1 (en) | Des-tyr dynorphin analogues | |
| US5605885A (en) | Method for stimulating the immune system | |
| Dafny et al. | Immune response products alter CNS acitivity: Interferon modulates central opioid function | |
| Mastino et al. | Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice | |
| Saphier et al. | α-Interferon inhibits adrenocortical secretion via μ1-opioid receptors in the rat | |
| Plotnikoff et al. | Neuroimmunomodulation with enkephalins: effects on thymus and spleen weights in mice | |
| US5534495A (en) | Treatment of non-HIV neuropathic pain syndromes | |
| AU2008282937A1 (en) | Methods of treating blood cell depletion | |
| AU660420B2 (en) | Method for treating immune system dysfunctions | |
| Fride et al. | Immunoenhancing effects of alprazolam in mice | |
| Greenberg et al. | Neurohormonal modulation of natural resistance to a murine lymphoma | |
| AU712606B2 (en) | Combined use of interleukin-10 and cyclosporin for immunosuppression therapy | |
| Yatsugi et al. | Anticonvulsive properties of YM-14673, a new TRH analogue, in amygdaloid-kindled rats | |
| WO1994012205A1 (en) | Dynorphin a suppression of natural killer cell activity | |
| US6022536A (en) | Combined use of interleukin 10 and cyclosporin for immunosuppression therapy | |
| Roy et al. | Dynorphin blocks opioid inhibition of macrophage-colony stimulating factor-induced proliferation of bone marrow cells | |
| Nicoletti et al. | Prevention of cyclophosphamide‐induced diabetes in the NOD/WEHI mouse with deoxyspergualin | |
| Deeg et al. | In vivo radioprotective effect of AcSDKP on canine myelopoiesis | |
| WO1993002692A1 (en) | Method of combatting hiv infections | |
| DE69117974T2 (de) | Pharmazeutische zusammensetzungen zur behandlung von b-zell-entartungen | |
| Nisticò et al. | Corticotropin-Releasing Factor Microinfused into the Locus coeruleus Produces Electrocortical Desynchronization and Immunosuppression. | |
| MXPA98001091A (en) | Combined use of interleukin-10 and cyclosporine for immunosupres therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |